Today's Drugs Gainers Led By Regeneron Pharmaceuticals Inc. (REGN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.2%. By the end of trading, Regeneron Pharmaceuticals rose $7.71 (3.7%) to $216.76 on heavy volume. Throughout the day, 1.2 million shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 745,400 shares. The stock ranged in a price between $210-$217.72 after having opened the day at $212 as compared to the previous trading day's close of $209.05. Other companies within the Drugs industry that increased today were: Idera Pharmaceuticals ( IDRA), up 19.6%, Oxygen Biotherapeutics ( OXBT), up 14.2%, Acorda Therapeutics ( ACOR), up 12.1%, and Bacterin International Holdings ( BONE), up 9.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $20.59 billion and is part of the health care sector. The company has a P/E ratio of 32, above the S&P 500 P/E ratio of 17.7. Shares are up 26.2% year to date as of the close of trading on Monday. Currently there are eight analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Sarepta Therapeutics ( SRPT), down 13.4%, Chemocentryx ( CCXI), down 9.7%, Cardium Therapeutics ( CXM), down 8.6%, and Biostar Pharmaceuticals ( BSPM), down 5.3%, were all laggards within the drugs industry with Forest Laboratories ( FRX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.

null

More from Markets

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes